Olga V. Sirotkina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Olga V. Sirotkina has a total of 146 co-authors. Here are the top co-authors by number of shared publications:
- Tatyana V. Vavilova
Almazov National Medical Research Center
15 shared publications - Elena V. Parmon
Almazov National Medical Research Center
5 shared publications - Galina A. Kukharchik
Almazov National Medical Research Centre
4 shared publications - Sofya N. Pchelina
Petersburg Nuclear Physics Institute Named by B.P. Konstantinov of National Research Centre «Kurchatov Institute», Gatchina 188300, Russia
4 shared publications T.V. Vavilova
Almazov National Medical Research Centre
4 shared publicationsA. B. Laskovets
Mechnikov North-West State Medical University, St. Petersburg, 191015 Russia
3 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Pharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- 31 October 2026
- Published by V.M. Bekhterev National Research Medical Center for Psychiatry and Neurology in V.M. BEKHTEREV REVIEW OF PSYCHIATRY AND MEDICAL PSYCHOLOGY
- Vol. 60 (5) , 70-87
Open AccessPharmacogenetic profile of the efficacy of agomelatine for stabilizing remission in patients with alcohol dependence and comorbid depressive disorders: results of a double-blind, randomized, placebo-controlled study
Alcohol dependence (AD) and depressive disorders (DD) exhibit a high level of comorbidity, significantly complicating treatment and worsening the clinical prognosis. The search for drugs that target the common pathogenetic mechanisms of these comorbid conditions is relevant. One such drug is agomelatine: an MT1 and MT2 melatonin receptor agonist and a 5-HT2C serotonin receptor antagonist. The identification of pharmacogenetic markers of agomelatine efficacy is an important goal in personalized therapy for comorbid AD and DD, as individual treatment response remains difficult to predict. Objective: To identify pharmacogenetic markers of agomelatine efficacy in patients with AD and comorbid DD. Materials and Methods. The pharmacogenetic study was conducted based on a 12-week, double-blind, randomized, placebo-controlled trial (N=100) of agomelatine efficacy in outpatients with AD and comorbid depression. The primary efficacy indicator was treatment retention, defined as the time (weeks) until discontinuation for any reason. The study’s genetic panel included 10 polymorphic loci in 8 genes: pharmacological targets of agomelatine — the melatonin receptors MT1 ( MTNR1A ) and MT2 ( MTNR1B ) and the serotonin receptor 5-HT2C ( HTR2C) , the gene encoding the cytochrome P450 enzyme CYP1A2 , which controls agomelatine pharmacokinetics, and key genes of the dopamine system (DRD2, ANKK1 ) and the endogenous opioid system ( OPRM1 , OPRK1 ). An analysis of associations between individual genetic variants and their combinations with the risk of early treatment discontinuation was performed within the dominant model in the agomelatine and placebo groups using Cox regression models. Hazard ratio (HR) with confidence intervals (CI) were calculated. Results. In the group of patients receiving agomelatine, an increased risk of early discontinuation of therapy, taking into account gender and age adjustment, was associated with carriage of the minor allele T rs2119882 in the MTNR1A gene [HR=2.25; 95%CI: (1.02–5.00); p=0.045], as well as with combinations of this variant with carriage of the minor allele A rs1800497 in the ANKK1 gene [HR=2.5; 95%CI: (1.16–5.61), p=0.019], the major genotype GG rs6275 in the DRD2 gene [HR=2.13; 95%CI: (1.02–4.46), p=0.045], the major genotype GG rs 10830963 in the MTNR1B gene [HR=2.10; 95%CI: (1.04–4.23), p=0.039], minor allele A rs2069514 in the CYP1A2*1C gene [HR=2.32; 95%CI: (1.01–5.35), p=0.048]. There was also an independent marker of the risk of dropping out of the therapy program in the form of a combination of minor alleles C rs762551 in the CYP1A2*1F gene and C rs6318 in the HTR2C gene [HR=3.32; 95%CI: (1.04–6.42), p=0.042]. No associations were found in the placebo group. Conclusion. The results of this study suggest that the pharmacogenetic response to agomelatine is polygenic in nature and is determined by the interaction of genes regulating the pharmacodynamics of the drug, its pharmacokinetics, and the neurobiological mechanisms of AD (reward cascade). The results of the study also might create a possibility to develop a polygenic pharmacogenetic panel that can be used for personalized approach to treatment of the patients with AD and comorbid depression with agomelatine.
- Open Access
- 9 June 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (1) , 94-107
Strokes and stroke risk factors in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) patients
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is pointed out from the group of small vessel diseases and its main feature is considered to be the development of stroke in the absence of well-known cardiovascular stroke risk factors. Nevertheless, such comorbid factors can be present in CADASIL patients. 71 genetically confirmed CADASIL patients were observed, in 31 of whom, a complex investigation including clinical, laboratory, molecular genetic, instrumental and neurovisualization data was performed, and 60 were tested for the presence of variants of polymorphisms in thrombophilic genes to detect their possible significance in development of a cerebral vascular accident. Thrombophilic gene’s testing was also performed in comparison groups including 45 patients with lacunar or small strokes and/or cerebral microangiopathy, and 309 persons who underwent laboratory genetic testing to exclude thrombophilia of a reference group. The results showed presence in CADASIL patients such coexisting stroke risk factors as arterial hypertension in 61.3 %, dyslipidemia in 64.5 %, obesity in 22.6 %, diabetes mellitus in 12.9 %, and smoking in 35.5 %. Other comorbidities included cardiovascular dysfunction presented mainly by cardiac conductive disability in 81.8 %, the signs of connective tissue dysplasia in 50.0 %, migraine in 74.2 %, and autoimmune thyroiditis in 22.6 %. In 78.3% of CADASIL patients, the simultaneous presence of 2-4 pathological alleles was revealed, and the pathological variant 103 G>T in the activated coagulation factor XIII (F13A) (p<0.05) encoding fibrinase was more common compared to the the reference group, which requires further studies as additional non modifiable stroke risk factors in CADASIL patients.
- 9 June 2026
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 33 (1) , 94-107
Open AccessStrokes and stroke risk factors in Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL) patients
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is pointed out from the group of small vessel diseases and its main feature is considered to be the development of stroke in the absence of well-known cardiovascular stroke risk factors. Nevertheless, such comorbid factors can be present in CADASIL patients. 71 genetically confirmed CADASIL patients were observed, in 31 of whom, a complex investigation including clinical, laboratory, molecular genetic, instrumental and neurovisualization data was performed, and 60 were tested for the presence of variants of polymorphisms in thrombophilic genes to detect their possible significance in development of a cerebral vascular accident. Thrombophilic gene’s testing was also performed in comparison groups including 45 patients with lacunar or small strokes and/or cerebral microangiopathy, and 309 persons who underwent laboratory genetic testing to exclude thrombophilia of a reference group. The results showed presence in CADASIL patients such coexisting stroke risk factors as arterial hypertension in 61.3 %, dyslipidemia in 64.5 %, obesity in 22.6 %, diabetes mellitus in 12.9 %, and smoking in 35.5 %. Other comorbidities included cardiovascular dysfunction presented mainly by cardiac conductive disability in 81.8 %, the signs of connective tissue dysplasia in 50.0 %, migraine in 74.2 %, and autoimmune thyroiditis in 22.6 %. In 78.3% of CADASIL patients, the simultaneous presence of 2-4 pathological alleles was revealed, and the pathological variant 103 G>T in the activated coagulation factor XIII (F13A) (p<0.05) encoding fibrinase was more common compared to the the reference group, which requires further studies as additional non modifiable stroke risk factors in CADASIL patients.
- 1 January 2026
- Published by Surgut State University in Vestnik SurGU. Meditsina
- Vol. 19 (3) , 89-96
GENETIC COMPONENT OF GERIATRIC SYNDROME IN PATIENTS WITH MYOCARDIAL ISCHEMIA
The study aims to determine the polyphaty structure in patients with non-ST elevation acute coronary syndrome (NSTE-ACS), depending on the presence of geriatric syndrome, in relation to the polymorphic variants C807T of the ITGA2 gene and T1565C of the ITGB3 gene. The research includes 103 patients with NSTE-ACS, aged over 60 years. All patients underwent a standard examination. In addition, the Charlson Comorbidity Index and the M. Hoover Frailty Index are determined. Genotyping of genomic deoxyribonucleic acid (DNA) samples from the study subjects is performed in real time using the DTprime Real-Time PCR Systems (DNA-Technology, Russia). Statistical processing is conducted on a MacOS computer with Microsoft Excel 2019, and subsequent data analysis utilizes IBM SPSS Statistics, version 26. The results show that in patients with NSTE-ACS, there is a tendency for certain genetic variants to prevail. In particular, the T allele of the ITGA2 gene (variant C807T) is more common, accounting for 61.1% to 72.7% of cases in all the studied groups. Similarly, the T allele of the ITGB3 gene (variant T1565C) is also more common, with a frequency of 86.1% to 91.2%. In patients who have had NSTE-ACS and exhibit geriatric syndrome, specific associations between gene polymorphisms and concomitant diseases are observed. In particular, the C allele of the ITGA2 gene (C807T) is more common in acute myocardial infarction, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease, while the T allele of this gene is associated with chronic kidney disease and anemia. The C allele of the ITGB3 gene (T1565C) is also associated with a range of diseases, including acute myocardial infarction, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, and anemia. Further investigation of polymorphisms C807T for the ITGA2 gene and T1565C for the ITGB3 gene and their correlation with clinical manifestations in patients with NSTE-ACS opens up prospects for creating a panel of genetic markers. This panel will make it possible to more effectively identify patients with a high risk of developing unfavorable variants of geriatric syndrome in the early stages, which will contribute to improving the prognosis and increasing the reversibility of pathological processes.
- 1 January 2026
- Published by Surgut State University in Vestnik SurGU. Meditsina
- Vol. 19 (3) , 89-96
GENETIC COMPONENT OF GERIATRIC SYNDROME IN PATIENTS WITH MYOCARDIAL ISCHEMIA
The study aims to determine the polyphaty structure in patients with non-ST elevation acute coronary syndrome (NSTE-ACS), depending on the presence of geriatric syndrome, in relation to the polymorphic variants C807T of the ITGA2 gene and T1565C of the ITGB3 gene. The research includes 103 patients with NSTE-ACS, aged over 60 years. All patients underwent a standard examination. In addition, the Charlson Comorbidity Index and the M. Hoover Frailty Index are determined. Genotyping of genomic deoxyribonucleic acid (DNA) samples from the study subjects is performed in real time using the DTprime Real-Time PCR Systems (DNA-Technology, Russia). Statistical processing is conducted on a MacOS computer with Microsoft Excel 2019, and subsequent data analysis utilizes IBM SPSS Statistics, version 26. The results show that in patients with NSTE-ACS, there is a tendency for certain genetic variants to prevail. In particular, the T allele of the ITGA2 gene (variant C807T) is more common, accounting for 61.1% to 72.7% of cases in all the studied groups. Similarly, the T allele of the ITGB3 gene (variant T1565C) is also more common, with a frequency of 86.1% to 91.2%. In patients who have had NSTE-ACS and exhibit geriatric syndrome, specific associations between gene polymorphisms and concomitant diseases are observed. In particular, the C allele of the ITGA2 gene (C807T) is more common in acute myocardial infarction, hypertension, diabetes mellitus, and chronic obstructive pulmonary disease, while the T allele of this gene is associated with chronic kidney disease and anemia. The C allele of the ITGB3 gene (T1565C) is also associated with a range of diseases, including acute myocardial infarction, hypertension, chronic kidney disease, chronic obstructive pulmonary disease, and anemia. Further investigation of polymorphisms C807T for the ITGA2 gene and T1565C for the ITGB3 gene and their correlation with clinical manifestations in patients with NSTE-ACS opens up prospects for creating a panel of genetic markers. This panel will make it possible to more effectively identify patients with a high risk of developing unfavorable variants of geriatric syndrome in the early stages, which will contribute to improving the prognosis and increasing the reversibility of pathological processes.
- Open Access
- 4 November 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (11) , 353
Pregnant Woman in Outcomes with Prosthetic Heart Valves
We here sought to assess thrombotic and hemorrhagic complications and associated risk factors during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV). Methods: The retrospective cohort study covered January 2011 to December 2022. The objective of the study was to assess the risk factors and frequency of thrombotic and hemorrhagic complications during pregnancy, delivery, and the postpartum period in women with PHV based on the experience of one perinatal center. We included 88 pregnancies with 77 prosthetic heart valves (PHV), which were divided into two groups, mechanical valve prostheses (MVP) (n = 64) and biological valve prosthesis (BVP) (n = 24). In the study we analyzed pregnancy outcomes, as well as thrombotic and hemorrhagic complication frequencies. Results: Of 88 pregnancies, 79 resulted in live births. In the MVP group, there were six miscarriages (9.4%) and two medical abortions (3.1%), including one due to Warfarin’s teratogenic effects. No miscarriages were reported in the BVP group, but one fetal mortality case (4.2%) occurred. During pregnancy, 11 MVP cases (17.2%) experienced thrombotic complications. In the BVP group, one patient (4.2%) had transient ischemic attack (TIA). Two MVP cases required surgical valve repair during pregnancy, and one in the post-delivery stage was caused by thrombotic complications. Postpartum, two MVP cases had strokes, and in one MVP patient, pulmonary embolism was registered, while no thrombotic complications occurred in the BVP group. Hemorrhagic complications affected 15 MVP cases (17.9%) in the postpartum period. There were no registered cases of maternal mortality. Conclusions: The effective control of anti-factor Xa activity reduced thrombotic events. However, the persistently high incidence of postpartum hemorrhagic complications suggests a need to reassess anticoagulant therapy regimens, lower target levels of anti-Xa, and reduce INR levels for discontinuing heparin bridge therapy. Despite the heightened mortality risk in MVP patients, our study cohort did not have any mortality cases, which contrasts with findings from other registries.
- 4 November 2024
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (11) , 353
Open AccessPregnant Woman in Outcomes with Prosthetic Heart Valves
We here sought to assess thrombotic and hemorrhagic complications and associated risk factors during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV). Methods: The retrospective cohort study covered January 2011 to December 2022. The objective of the study was to assess the risk factors and frequency of thrombotic and hemorrhagic complications during pregnancy, delivery, and the postpartum period in women with PHV based on the experience of one perinatal center. We included 88 pregnancies with 77 prosthetic heart valves (PHV), which were divided into two groups, mechanical valve prostheses (MVP) (n = 64) and biological valve prosthesis (BVP) (n = 24). In the study we analyzed pregnancy outcomes, as well as thrombotic and hemorrhagic complication frequencies. Results: Of 88 pregnancies, 79 resulted in live births. In the MVP group, there were six miscarriages (9.4%) and two medical abortions (3.1%), including one due to Warfarin’s teratogenic effects. No miscarriages were reported in the BVP group, but one fetal mortality case (4.2%) occurred. During pregnancy, 11 MVP cases (17.2%) experienced thrombotic complications. In the BVP group, one patient (4.2%) had transient ischemic attack (TIA). Two MVP cases required surgical valve repair during pregnancy, and one in the post-delivery stage was caused by thrombotic complications. Postpartum, two MVP cases had strokes, and in one MVP patient, pulmonary embolism was registered, while no thrombotic complications occurred in the BVP group. Hemorrhagic complications affected 15 MVP cases (17.9%) in the postpartum period. There were no registered cases of maternal mortality. Conclusions: The effective control of anti-factor Xa activity reduced thrombotic events. However, the persistently high incidence of postpartum hemorrhagic complications suggests a need to reassess anticoagulant therapy regimens, lower target levels of anti-Xa, and reduce INR levels for discontinuing heparin bridge therapy. Despite the heightened mortality risk in MVP patients, our study cohort did not have any mortality cases, which contrasts with findings from other registries.
- Open Access
- 27 August 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (7) , 5708
Clusters of patients with non-ST-segment elevation acute coronary syndrome depending on the laboratory data
Aim. To identify clusters of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) depending on the laboratory data, including platelet function tests.Material and methods. The study included 109 patients hospitalized in the cardiology department with NSTE-ACS. All patients underwent a standard examination, including a complete blood count. In addition, the platelet function was assessed using impedance aggregometry with various inducers (adenosine diphosphate (5 and 10 μmol/L), collagen (2 μmol/L)). We assessed the P-selectin expression level using flow cytometry. Patients were followed up for 6 months. As a statistical method, we performed сluster analysis by K-means algorithm.Results. We registered 18 adverse outcomes (myocardial infarction, unstable angina) during 6-month follow-up. Cluster analysis revealed 3 clusters. The first cluster included 39 (36%) patients with higher monocyte values and lower hemoglobin values, probably indicating chronic inflammation and a tendency towards anemia. The second cluster included 13 older patients (12%) with high comorbidity and high platelet function. Both the first and second clusters recorded 23% adverse outcomes. Third cluster, on the contrary, included mostly younger patients with fewer comorbidities, which had more favorable course of ACS (no signs of platelet hyperaggregation, chronic inflammation and anemia). This cluster included more than half (n=57, 52%) of all patients; adverse outcomes at 6 months in these patients developed 2-fold less frequently than in the other clusters (11% vs 23%).Conclusion. Among patients with NSTE-ACS, groups differing in laboratory parameters were identified, based on which clusters were formed using the k-means method. Clusters with high levels of platelet functional activity, monocyte count and low hemoglobin values included older patients with severe comorbidity and showed a tendency towards more frequent adverse outcomes of the disease.
- 27 August 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (7) , 5708
Open AccessClusters of patients with non-ST-segment elevation acute coronary syndrome depending on the laboratory data
Aim. To identify clusters of patients with non-ST segment elevation acute coronary syndrome (NSTE-ACS) depending on the laboratory data, including platelet function tests.Material and methods. The study included 109 patients hospitalized in the cardiology department with NSTE-ACS. All patients underwent a standard examination, including a complete blood count. In addition, the platelet function was assessed using impedance aggregometry with various inducers (adenosine diphosphate (5 and 10 μmol/L), collagen (2 μmol/L)). We assessed the P-selectin expression level using flow cytometry. Patients were followed up for 6 months. As a statistical method, we performed сluster analysis by K-means algorithm.Results. We registered 18 adverse outcomes (myocardial infarction, unstable angina) during 6-month follow-up. Cluster analysis revealed 3 clusters. The first cluster included 39 (36%) patients with higher monocyte values and lower hemoglobin values, probably indicating chronic inflammation and a tendency towards anemia. The second cluster included 13 older patients (12%) with high comorbidity and high platelet function. Both the first and second clusters recorded 23% adverse outcomes. Third cluster, on the contrary, included mostly younger patients with fewer comorbidities, which had more favorable course of ACS (no signs of platelet hyperaggregation, chronic inflammation and anemia). This cluster included more than half (n=57, 52%) of all patients; adverse outcomes at 6 months in these patients developed 2-fold less frequently than in the other clusters (11% vs 23%).Conclusion. Among patients with NSTE-ACS, groups differing in laboratory parameters were identified, based on which clusters were formed using the k-means method. Clusters with high levels of platelet functional activity, monocyte count and low hemoglobin values included older patients with severe comorbidity and showed a tendency towards more frequent adverse outcomes of the disease.
- Open Access
- 17 October 2023
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 10 (4) , 252-263
Relationship of comorbidity and platelet function in patients with unstable angina
Background. Platelets play a key role in the pathogenesis of acute coronary syndrome (ACS). In recent years, the amount of data on the advisability of using the platelet function test (PFT) in the appointment of antithrombotic therapy has been growing.Objective. To access PFT in patients with unstable angina and various comorbidities.Design and methods. The study involved 74 patients with the diagnosis of unstable angina. All patients underwent standard clinical examination, PFT (impedance aggregometry with ADP and collagen), assessment of Charlson comorbidity index.Results. The most frequent comorbidities were: hypertension (95 %), type 2 diabetes mellitus (30 %), excessive body weight (35 %), multifocal atherosclerosis (22 %), smoking (24 %). Half of the patients (n = 36) had high level of comorbidity. Patients with a comorbidity index of 5 or more had high platelet aggregation on the 3rd day of hospitalization. Elderly patients, smokers, as well as patients with diabetes mellitus type 2 and multifocal atherosclerosis also had higher values of platelet activity, which may be associated with unfavorable prognosis and risk of recurrent events.Conclusion. We revealed association between PFT and comorbidities both with risk factors or diseases alone and in its integral assessment using the Charlson comorbidity index. Among the individual risk factors, smoking, diabetes mellitus and multifocal atherosclerosis were the most important, which confirms their direct role in the pathogenesis of thrombotic complications.
- 17 October 2023
- Published by Arterialnaya Gipertenziya in Translational Medicine
- Vol. 10 (4) , 252-263
Open AccessRelationship of comorbidity and platelet function in patients with unstable angina
Background. Platelets play a key role in the pathogenesis of acute coronary syndrome (ACS). In recent years, the amount of data on the advisability of using the platelet function test (PFT) in the appointment of antithrombotic therapy has been growing.Objective. To access PFT in patients with unstable angina and various comorbidities.Design and methods. The study involved 74 patients with the diagnosis of unstable angina. All patients underwent standard clinical examination, PFT (impedance aggregometry with ADP and collagen), assessment of Charlson comorbidity index.Results. The most frequent comorbidities were: hypertension (95 %), type 2 diabetes mellitus (30 %), excessive body weight (35 %), multifocal atherosclerosis (22 %), smoking (24 %). Half of the patients (n = 36) had high level of comorbidity. Patients with a comorbidity index of 5 or more had high platelet aggregation on the 3rd day of hospitalization. Elderly patients, smokers, as well as patients with diabetes mellitus type 2 and multifocal atherosclerosis also had higher values of platelet activity, which may be associated with unfavorable prognosis and risk of recurrent events.Conclusion. We revealed association between PFT and comorbidities both with risk factors or diseases alone and in its integral assessment using the Charlson comorbidity index. Among the individual risk factors, smoking, diabetes mellitus and multifocal atherosclerosis were the most important, which confirms their direct role in the pathogenesis of thrombotic complications.
- Open Access
- 19 July 2023
- Published by Publishing House OKI in Pharmacogenetics and Pharmacogenomics
- No. 1,p. 20-32
The microRNA-144/451 cluster in plasma-derived microvesicles and erythrocytes in patients with history of pulmonary embolism
Chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH) are the complications that comprise a serious problem for patients with history of pulmonary embolism (PE). Erythrocytes, extracellular microvesicles (EMVs) and miRNAs play a substantial role in the procoagulant states. The aim. To analyze the levels of miR-144-3р, miR-451a, and miR-451b in blood plasma-derived EMVs and erythrocytes in patients with history of PE and in the control group. Materials and Methods. 18 patients with history of PE (13 CTEPH, 5 CTED) and 8 controls were enrolled into the study. All the participants had undergone clinical and biochemical blood tests as well as the coagulogram. We used flow cytometry to assess plasma-derived EMVs (CD9, CD41, CD45, CD235a, CD105). We measured the expression of miR-144-3р, miR-451a, miR-451b by real-time PCR with endogenous control (miR-152-3p) and five exogenous quality controls. Results. The levels of miR-144-3р and miR-451a in patients were lower than in controls, both in EMVs (р = 0.030; р = 0.065) and in erythrocytes (р = 0.023;р = 0.086). In female patients, the levels of miR-144-3р and miR-451a in CTEPH were lower than in CTED (р = 0.087; р = 0.031). Mir-451b in EMVs has not been detected, while in erythrocytes its levels have not differed between the groups. In patients, the levels of miR-144-3р and miR-451a directly correlated with each other both in EMVs (р = 0.004) and in erythrocytes (р = 0.042). In all the participants, the levels of miR-144-3р and miR-451a in EMVs directly correlated with those in erythrocytes (р = 0.002; р = 0.078). The number of erythrocyte-derived EMVs correlated with miR-451a levels both in EMVs (R = 0.472; p = 0.065) and in erythrocytes (R = –0.829; p = 0.011). The level of miR-451a in EMVs correlated with blood plasma levels of factor VIII and fibrinogen (R = 0.584; p = 0.022 and R= –0.489; p = 0.047), and with the International Normalized Ratio (R = 0.894; p = 0.041). Conclusion. The microRNA-144/451 cluster may influence both the hemostasis system and the risk of post-thromboembolic complications development. In the present study, miR-144-3р and miR-451a showed themselves as protective factors in relation to both the development of PE and severity of post-thromboembolic complications.
- 19 July 2023
- Published by Publishing House OKI in Pharmacogenetics and Pharmacogenomics
- No. 1,p. 20-32
Open AccessThe microRNA-144/451 cluster in plasma-derived microvesicles and erythrocytes in patients with history of pulmonary embolism
Chronic thromboembolic disease (CTED) and chronic thromboembolic pulmonary hypertension (CTEPH) are the complications that comprise a serious problem for patients with history of pulmonary embolism (PE). Erythrocytes, extracellular microvesicles (EMVs) and miRNAs play a substantial role in the procoagulant states. The aim. To analyze the levels of miR-144-3р, miR-451a, and miR-451b in blood plasma-derived EMVs and erythrocytes in patients with history of PE and in the control group. Materials and Methods. 18 patients with history of PE (13 CTEPH, 5 CTED) and 8 controls were enrolled into the study. All the participants had undergone clinical and biochemical blood tests as well as the coagulogram. We used flow cytometry to assess plasma-derived EMVs (CD9, CD41, CD45, CD235a, CD105). We measured the expression of miR-144-3р, miR-451a, miR-451b by real-time PCR with endogenous control (miR-152-3p) and five exogenous quality controls. Results. The levels of miR-144-3р and miR-451a in patients were lower than in controls, both in EMVs (р = 0.030; р = 0.065) and in erythrocytes (р = 0.023;р = 0.086). In female patients, the levels of miR-144-3р and miR-451a in CTEPH were lower than in CTED (р = 0.087; р = 0.031). Mir-451b in EMVs has not been detected, while in erythrocytes its levels have not differed between the groups. In patients, the levels of miR-144-3р and miR-451a directly correlated with each other both in EMVs (р = 0.004) and in erythrocytes (р = 0.042). In all the participants, the levels of miR-144-3р and miR-451a in EMVs directly correlated with those in erythrocytes (р = 0.002; р = 0.078). The number of erythrocyte-derived EMVs correlated with miR-451a levels both in EMVs (R = 0.472; p = 0.065) and in erythrocytes (R = –0.829; p = 0.011). The level of miR-451a in EMVs correlated with blood plasma levels of factor VIII and fibrinogen (R = 0.584; p = 0.022 and R= –0.489; p = 0.047), and with the International Normalized Ratio (R = 0.894; p = 0.041). Conclusion. The microRNA-144/451 cluster may influence both the hemostasis system and the risk of post-thromboembolic complications development. In the present study, miR-144-3р and miR-451a showed themselves as protective factors in relation to both the development of PE and severity of post-thromboembolic complications.
- 22 May 2023
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 1 (1) , 107-114
The study of platelet microparticles and P-selectin expression in patients with the peripheral arterial diseases
BACKGROUND: High platelet reactivity leads to the progression of atherosclerosis and its complications. Activated platelets adhere to the site of endothelium damage on the vessel wall and initiate the formation of an arterial thrombus, followed by acute ischemia of the organ. Biochemical and cellular marker such as platelet microvesicles and P-selectin can be analyzed using flow cytometry, which is based on a specific antigen-antibody interaction. Patients with peripheral arterial disease are at significantly greater risk of cardiovascular and cerebrovascular complications than individuals of the same age and sex. The use of antiplatelet agents is an important part of pathogenetic therapy and prevention of cardiovascular diseases and their complications. AIM: This study was to evaluate the level of platelet microparticles and P-selectin expression in patients with peripheral arterial disease receiving antiplatelet therapy. MATERIALS AND METHODS: The study included 49 people, which included three study groups: patients with obliterating disease of the arteries of the lower extremities (n = 14) on the background of long-term use (more than 14 days) of double (75 mg clopidogrel and 100 mg Acetylsalicylic acid) antiplatelet therapy, patients with COVID-19 (n = 15), who made up the positive control group in the determination of microparticles of platelet origin, and healthy volunteers (n = 20) without signs of acute respiratory disease, without a history of cardiovascular and thromboembolic episodes, not taking antiplatelet drugs. The functional activity of platelets was assessed by two methods: using light aggregometry and analysis of P-selectin expression on platelet surface by flow cytometry. The number of platelets microparticles in blood plasma was also determined using flow cytometry. RESULTS: A significant decrease in platelet aggregation was found in patients with peripheral arterial disease taking antiplatelet agents, compared with controls by used light aggregometry. Similar changes were obtained when analyzing the expression of P-selectin on platelets. A higher percentage of platelets microparticles with the CD9+CD41+ phenotype was found in patients with severe inflammation compared with peripheral arterial disease patients treated with antiplatelet agents and compared with the healthy controls. CONCLUSIONS: Thus, our study reflects the consistency of the results of three different laboratory tests in assessing the platelets reactivity in patients with the peripheral arterial diseases taking antiplatelet drugs.
- 22 May 2023
- Published by ECO-Vector LLC in Medical academic journal
- Vol. 1 (1) , 107-114
The study of platelet microparticles and P-selectin expression in patients with the peripheral arterial diseases
BACKGROUND: High platelet reactivity leads to the progression of atherosclerosis and its complications. Activated platelets adhere to the site of endothelium damage on the vessel wall and initiate the formation of an arterial thrombus, followed by acute ischemia of the organ. Biochemical and cellular marker such as platelet microvesicles and P-selectin can be analyzed using flow cytometry, which is based on a specific antigen-antibody interaction. Patients with peripheral arterial disease are at significantly greater risk of cardiovascular and cerebrovascular complications than individuals of the same age and sex. The use of antiplatelet agents is an important part of pathogenetic therapy and prevention of cardiovascular diseases and their complications. AIM: This study was to evaluate the level of platelet microparticles and P-selectin expression in patients with peripheral arterial disease receiving antiplatelet therapy. MATERIALS AND METHODS: The study included 49 people, which included three study groups: patients with obliterating disease of the arteries of the lower extremities (n = 14) on the background of long-term use (more than 14 days) of double (75 mg clopidogrel and 100 mg Acetylsalicylic acid) antiplatelet therapy, patients with COVID-19 (n = 15), who made up the positive control group in the determination of microparticles of platelet origin, and healthy volunteers (n = 20) without signs of acute respiratory disease, without a history of cardiovascular and thromboembolic episodes, not taking antiplatelet drugs. The functional activity of platelets was assessed by two methods: using light aggregometry and analysis of P-selectin expression on platelet surface by flow cytometry. The number of platelets microparticles in blood plasma was also determined using flow cytometry. RESULTS: A significant decrease in platelet aggregation was found in patients with peripheral arterial disease taking antiplatelet agents, compared with controls by used light aggregometry. Similar changes were obtained when analyzing the expression of P-selectin on platelets. A higher percentage of platelets microparticles with the CD9+CD41+ phenotype was found in patients with severe inflammation compared with peripheral arterial disease patients treated with antiplatelet agents and compared with the healthy controls. CONCLUSIONS: Thus, our study reflects the consistency of the results of three different laboratory tests in assessing the platelets reactivity in patients with the peripheral arterial diseases taking antiplatelet drugs.
- Open Access
- 13 May 2022
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 29 (1) , 28-36
Correlation of laboratory markers of hemostatic system activation with concentration and size of plasma extracellular microparticles in patients with COVID-19
Introduction. In recent years, much attention has been paid to the study of extracellular microparticles (microvesicles and exosomes) and their role in the pathogenesis of human diseases.The objective of this study was to determine the number and size of plasma extracellular microparticles (PEMP) in patients with severe and extremely severe COVID-19 and correlate these data with the markers of hemostasis activation, inflammation, and tissue damage.Methods and Materials. The study included 29 patients with severe and extremely severe COVID-19. Concentration and size of PEMP were determined by nanoparticle trajectory analysis (NTA). All patients underwent the complete blood count and the thromboelastometry (TEM). Hemostatic, biochemical, and immunological parameters were assessed including fibrinogen, prothrombin time, activated partial thromboplastin time, D-dimer, C-reactive protein, lactate dehydrogenase, procalcitonin, von Willebrand factor antigen, interleukin 6, and interleukin 18.Results. There were 14 patients (48.3 %) discharged from the ICU with improvement (group 1— survived patients), and 15 patients (51.7 %) with lethal outcomes (group 2 — lethal outcome); the PEMP concentration did not differ between these groups. In group 2, there were heterogeneity of PEMP population, and a tendency to the larger PEMP size (p=0.074). In all patients, the PEMP concentration correlated negatively with both prothrombin time and the number of large platelets; the size of PEMP correlated negatively with the level of von Willebrand factor antigen, and positively with the fibrinogen. In group 1, the PEMP concentration had a direct correlation with both the level of interleukin 18 and maximum clot lysis in TEM; the PEMP size had a direct correlation with the maximum clot lysis in TEM and an inverse correlation with both the level of procalcitonin and maximum clot density in TEM.Conclusion. Our study confirms the importance of the process of extracellular microparticles formation in the COVID-19 pathogenesis. Our findings are consistent with the hypothesis that the parameters of PEMP population can be predictive biomarkers of the COVID-19 severity.
- 13 May 2022
- Published by FSBEI HE I.P. Pavlov SPbSMU MOH Russia in The Scientific Notes of the Pavlov University
- Vol. 29 (1) , 28-36
Open AccessCorrelation of laboratory markers of hemostatic system activation with concentration and size of plasma extracellular microparticles in patients with COVID-19
Introduction. In recent years, much attention has been paid to the study of extracellular microparticles (microvesicles and exosomes) and their role in the pathogenesis of human diseases.The objective of this study was to determine the number and size of plasma extracellular microparticles (PEMP) in patients with severe and extremely severe COVID-19 and correlate these data with the markers of hemostasis activation, inflammation, and tissue damage.Methods and Materials. The study included 29 patients with severe and extremely severe COVID-19. Concentration and size of PEMP were determined by nanoparticle trajectory analysis (NTA). All patients underwent the complete blood count and the thromboelastometry (TEM). Hemostatic, biochemical, and immunological parameters were assessed including fibrinogen, prothrombin time, activated partial thromboplastin time, D-dimer, C-reactive protein, lactate dehydrogenase, procalcitonin, von Willebrand factor antigen, interleukin 6, and interleukin 18.Results. There were 14 patients (48.3 %) discharged from the ICU with improvement (group 1— survived patients), and 15 patients (51.7 %) with lethal outcomes (group 2 — lethal outcome); the PEMP concentration did not differ between these groups. In group 2, there were heterogeneity of PEMP population, and a tendency to the larger PEMP size (p=0.074). In all patients, the PEMP concentration correlated negatively with both prothrombin time and the number of large platelets; the size of PEMP correlated negatively with the level of von Willebrand factor antigen, and positively with the fibrinogen. In group 1, the PEMP concentration had a direct correlation with both the level of interleukin 18 and maximum clot lysis in TEM; the PEMP size had a direct correlation with the maximum clot lysis in TEM and an inverse correlation with both the level of procalcitonin and maximum clot density in TEM.Conclusion. Our study confirms the importance of the process of extracellular microparticles formation in the COVID-19 pathogenesis. Our findings are consistent with the hypothesis that the parameters of PEMP population can be predictive biomarkers of the COVID-19 severity.